The State Food and Drug Administration approved the listing of darcilil hydroxyethanesulfonate tablets
Financial Associated Press, Dec. 31 (Xinhua) -- recently, the State Drug Administration approved the listing of class 1 innovative drug darcilil hydroxyethanesulfonate tablets (trade name: arikang) declared by Jiangsu Hengrui Pharmaceutical Co., Ltd. through the priority review and approval procedure. The drug combined with fluticasone is suitable for patients with recurrent or metastatic breast cancer with hormone receptor positive and human epidermal growth factor receptor 2 negative after previous endocrine therapy. Dalpiciclib is a cyclin dependent kinase 4 and 6 (CDK4 and Cdk6) inhibitor, which can reduce the phosphorylation level of retinoblastoma protein downstream of CDK4 and Cdk6 signaling pathway and induce G1 phase arrest, so as to inhibit the proliferation of tumor cells. The listing of the drug provides a new treatment option for breast cancer patients.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Briefing Apr 25, 2022 06:25 PM
· Healthcare
Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
Apr 18, 2022 06:30 PM
Apr 22, 2021 03:11 PM
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Briefing Apr 25, 2022 09:45 AM
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Financials, Healthcare
Ophthalmological Medtech Startup Raises Tens of Mns of CNY in Series C Funding
Founded in 2011, Suzhou Microclear Medical is engaged in the ophthalmology and optometry imaging field. Microclear integrates self-developed components with artificial intelligence technology to provide high-quality devices and services for hospitals and basic medical institutes across the world.
Updated 59 mins ago
Healthcare, Financials
Electrophysiology AccuPulse Raises Nearly CNY 100 Million in Series A Funding
Founded in November 2020, Suzhou AccuPulse is committed to becoming an international leading platform-based innovative cardiac electrophysiology company. The company has established a research and development team led by well-known electrophysiological experts in the US with R&D centers in Suzhou and in the United States.
May 20, 2022 05:17 PM
Briefing Mar 14, 2022 07:48 AM
· Healthcare
Defining key tasks and accelerating the construction of new urbanization
Healthcare · Analysis
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
See more
Read next
In-depth
In-depth
Technology
Exclusive Interview with Liu Di, Managing Director of Peakview Capital
May 21, 2022 12:51 PM
In-depth
In-depth
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.